Drug General Information
Drug ID
D0G7OZ
Former ID
DIB020743
Drug Name
pobilukast
Synonyms
SKF 104353
Drug Type
Small molecular drug
Indication Discovery agent Investigative [540293]
Structure
Download
2D MOL
Formula
C26H34O5S
InChI
InChI=1S/C26H34O5S/c27-23(28)18-19-32-25(24(29)26(30)31)22-17-11-10-16-21(22)15-9-4-2-1-3-6-12-20-13-7-5-8-14-20/h5,7-8,10-11,13-14,16-17,24-25,29H,1-4,6,9,12,15,18-19H2,(H,27,28)(H,30,31)/t24-,25-/m1/s1
InChIKey
PZIFPMYXXCAOCC-JWQCQUIFSA-N
PubChem Compound ID
PubChem Substance ID
Target and Pathway
Target(s) Leukotriene CysLT2 receptor Target Info Antagonist [543686]
Cysteinyl leukotriene receptor 1 Target Info Antagonist [525572]
KEGG Pathway Calcium signaling pathway
Neuroactive ligand-receptor interactionhsa04020:Calcium signaling pathway
Neuroactive ligand-receptor interaction
NetPath Pathway IL4 Signaling Pathway
IL3 Signaling PathwayNetPath_7:TGF_beta_Receptor Signaling Pathway
IL3 Signaling Pathway
Pathway Interaction Database Endothelinsendothelinpathway:Endothelins
Reactome Leukotriene receptors
G alpha (q) signalling eventsR-HSA-391906:Leukotriene receptors
G alpha (q) signalling events
WikiPathways GPCRs, Class A Rhodopsin-like
Gastrin-CREB signalling pathway via PKC and MAPK
GPCR ligand binding
GPCR downstream signalingWP455:GPCRs, Class A Rhodopsin-like
GPCR downstream signaling
References
Ref 540293(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3334).
Ref 525572Identification, molecular cloning, expression, and characterization of a cysteinyl leukotriene receptor. Mol Pharmacol. 1999 Sep;56(3):657-63.
Ref 543686(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 270).

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.